Lv6
1760 积分 2023-03-30 加入
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
9小时前
待确认
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
10小时前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
10小时前
已完结
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
10小时前
已完结
Evaluation of risk factors and survival rates of patients with early-stage breast cancer with machine learning and traditional methods
10天前
已完结
Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) - biology, clinical results and future directions
13天前
已完结
Evolving roles of MET as a therapeutic target in NSCLC and beyond
14天前
已完结
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
21天前
已完结
Modified anterior intercostal artery perforator flap (AICAP) for autologous breast volume restoration after explantation
24天前
已完结
Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery
24天前
已完结
皖公网安备34019202002308
